Cargando…

Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy

Prevention of chemotherapy-induced nausea and vomiting (CINV) is a key component of treatment for patients with cancer. Guidelines are available to assist prescribers in the management of CINV associated with single-day chemotherapy regimens. However, currently there are no clear guidelines for mana...

Descripción completa

Detalles Bibliográficos
Autores principales: Affronti, Mary Lou, Bubalo, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161526/
https://www.ncbi.nlm.nih.gov/pubmed/25228819
http://dx.doi.org/10.2147/CMAR.S68102
_version_ 1782334576851419136
author Affronti, Mary Lou
Bubalo, Joseph
author_facet Affronti, Mary Lou
Bubalo, Joseph
author_sort Affronti, Mary Lou
collection PubMed
description Prevention of chemotherapy-induced nausea and vomiting (CINV) is a key component of treatment for patients with cancer. Guidelines are available to assist prescribers in the management of CINV associated with single-day chemotherapy regimens. However, currently there are no clear guidelines for management of CINV in patients receiving multiple-day chemotherapy regimens. Serotonin (5-HT(3)) receptor antagonists are a mainstay in preventing CINV, and palonosetron, given its longer half-life and duration of action relative to other 5-HT(3) receptor antagonists, may be a useful option for managing CINV in multiple-day chemotherapy. Here we provide an overview of CINV and CINV treatment options, with a focus on palonosetron. We describe existing challenges in managing CINV, and discuss two patients receiving multiple-day chemotherapy, in whom CINV was managed successfully with palonosetron.
format Online
Article
Text
id pubmed-4161526
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-41615262014-09-16 Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy Affronti, Mary Lou Bubalo, Joseph Cancer Manag Res Review Prevention of chemotherapy-induced nausea and vomiting (CINV) is a key component of treatment for patients with cancer. Guidelines are available to assist prescribers in the management of CINV associated with single-day chemotherapy regimens. However, currently there are no clear guidelines for management of CINV in patients receiving multiple-day chemotherapy regimens. Serotonin (5-HT(3)) receptor antagonists are a mainstay in preventing CINV, and palonosetron, given its longer half-life and duration of action relative to other 5-HT(3) receptor antagonists, may be a useful option for managing CINV in multiple-day chemotherapy. Here we provide an overview of CINV and CINV treatment options, with a focus on palonosetron. We describe existing challenges in managing CINV, and discuss two patients receiving multiple-day chemotherapy, in whom CINV was managed successfully with palonosetron. Dove Medical Press 2014-09-05 /pmc/articles/PMC4161526/ /pubmed/25228819 http://dx.doi.org/10.2147/CMAR.S68102 Text en © 2014 Affronti and Bubalo. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Affronti, Mary Lou
Bubalo, Joseph
Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy
title Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy
title_full Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy
title_fullStr Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy
title_full_unstemmed Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy
title_short Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy
title_sort palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161526/
https://www.ncbi.nlm.nih.gov/pubmed/25228819
http://dx.doi.org/10.2147/CMAR.S68102
work_keys_str_mv AT affrontimarylou palonosetroninthemanagementofchemotherapyinducednauseaandvomitinginpatientsreceivingmultipledaychemotherapy
AT bubalojoseph palonosetroninthemanagementofchemotherapyinducednauseaandvomitinginpatientsreceivingmultipledaychemotherapy